Healthcare provider profile · identity verified

Christopher Jon Doan, M.D.

Family Practice · MERIDEN, CT · NPI 1871754945

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	695	152
Amlodipine Besylate	Amlodipine Besylate	452	113
Lisinopril	Lisinopril	441	101
Levothyroxine Sodium	Levothyroxine Sodium	367	79
Metformin Hcl	Metformin Hcl	327	79
Hydrochlorothiazide	Hydrochlorothiazide	297	69
Pantoprazole Sodium	Pantoprazole Sodium	242	53
Losartan Potassium	Losartan Potassium	219	56
Simvastatin	Simvastatin	214	53
Allopurinol	Allopurinol	195	55
Tamsulosin Hcl	Tamsulosin Hcl	177	46
Omeprazole	Omeprazole	162	36
Ozempic	Semaglutide	148	30
Rosuvastatin Calcium	Rosuvastatin Calcium	148	45
Escitalopram Oxalate	Escitalopram Oxalate	146	34
Glipizide Er	Glipizide	128	23
Gabapentin	Gabapentin	127	53
Metoprolol Tartrate	Metoprolol Tartrate	118	32
Sertraline Hcl	Sertraline Hcl	114	25
Farxiga	Dapagliflozin Propanediol	113	22
Metoprolol Succinate	Metoprolol Succinate	111	29
Trazodone Hcl	Trazodone Hcl	106	33
Montelukast Sodium	Montelukast Sodium	103	29
Albuterol Sulfate Hfa	Albuterol Sulfate	101	40
Alendronate Sodium	Alendronate Sodium	101	27
Fluticasone Propionate	Fluticasone Propionate	100	43
Pravastatin Sodium	Pravastatin Sodium	100	23
Metformin Hcl Er	Metformin Hcl	99	30
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	82	12
Jardiance	Empagliflozin	80	26
Zolpidem Tartrate	Zolpidem Tartrate	78	21
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	75	22
Finasteride	Finasteride	69	23
Furosemide	Furosemide	67	28
Esomeprazole Magnesium	Esomeprazole Magnesium	66	15
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	65	15
Alprazolam	Alprazolam	64	23
Glimepiride	Glimepiride	63	17
Valsartan	Valsartan	58	16
Tramadol Hcl	Tramadol Hcl	54	13
Enalapril Maleate	Enalapril Maleate	53	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	53	suppressed
Mirtazapine	Mirtazapine	48	16
Famotidine	Famotidine	47	12
Atenolol	Atenolol	46	16
Duloxetine Hcl	Duloxetine Hcl	45	18
Lorazepam	Lorazepam	44	23
Oxybutynin Chloride Er	Oxybutynin Chloride	42	suppressed
Prednisone	Prednisone	41	35
Doxycycline Monohydrate	Doxycycline Monohydrate	40	36
Tizanidine Hcl	Tizanidine Hcl	40	17
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	39	13
Fluoxetine Hcl	Fluoxetine Hcl	38	suppressed
Carvedilol	Carvedilol	37	suppressed
Pregabalin	Pregabalin	36	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	34	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	34	suppressed
Xarelto	Rivaroxaban	33	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	32	27
Benazepril Hcl	Benazepril Hcl	32	11
Lovastatin	Lovastatin	31	suppressed
Meclizine Hcl	Meclizine Hcl	31	19
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	30	suppressed
Spironolactone	Spironolactone	30	12
Tradjenta	Linagliptin	30	suppressed
Januvia	Sitagliptin Phosphate	29	suppressed
Meloxicam	Meloxicam	28	suppressed
Fenofibrate	Fenofibrate	27	suppressed
Baclofen	Baclofen	26	suppressed
Fluvoxamine Maleate	Fluvoxamine Maleate	26	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	26	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	26	suppressed
Clonazepam	Clonazepam	25	11
Hydralazine Hcl	Hydralazine Hcl	25	suppressed
Nystatin	Nystatin	25	12
Olmesartan Medoxomil	Olmesartan Medoxomil	25	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	25	12
Tresiba Flextouch U-100	Insulin Degludec	24	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	23	suppressed
Eliquis	Apixaban	23	suppressed
Oxycodone Hcl	Oxycodone Hcl	23	suppressed
Ropinirole Hcl	Ropinirole Hcl	23	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	22	11
Bupropion Xl	Bupropion Hcl	21	suppressed
Clopidogrel	Clopidogrel Bisulfate	21	suppressed
Levemir Flexpen	Insulin Detemir	21	suppressed
Chlorthalidone	Chlorthalidone	20	suppressed
Colchicine	Colchicine	20	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	20	suppressed
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	20	suppressed
Synthroid	Levothyroxine Sodium	19	suppressed
Ventolin Hfa	Albuterol Sulfate	19	suppressed
Clonidine Hcl	Clonidine Hcl	18	suppressed
Humalog Kwikpen U-100	Insulin Lispro	18	suppressed
Buspirone Hcl	Buspirone Hcl	17	suppressed
Ketoconazole	Ketoconazole	17	suppressed
Mometasone Furoate	Mometasone Furoate	17	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	17	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	17	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	16	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	16	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	16	suppressed
Divalproex Sodium	Divalproex Sodium	15	suppressed
Bupropion Hcl Sr	Bupropion Hcl	14	suppressed
Ezetimibe	Ezetimibe	14	suppressed
Ibandronate Sodium	Ibandronate Sodium	14	suppressed
Incruse Ellipta	Umeclidinium Bromide	14	suppressed
Sildenafil Citrate	Sildenafil Citrate	14	suppressed
Citalopram Hbr	Citalopram Hydrobromide	13	suppressed
Novolog Flexpen	Insulin Aspart	13	suppressed
Aripiprazole	Aripiprazole	12	suppressed
Bumetanide	Bumetanide	12	suppressed
Clobetasol Propionate	Clobetasol Propionate	12	suppressed
Diazepam	Diazepam	12	suppressed
Diclofenac Sodium	Diclofenac Sodium	12	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	12	suppressed
Flecainide Acetate	Flecainide Acetate	12	suppressed
Ramipril	Ramipril	12	suppressed
Valacyclovir	Valacyclovir Hcl	12	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	11	suppressed
Memantine Hcl	Memantine Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error